Woodline Partners’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.4M Buy
+969,389
New +$26.4M 0.07% 355
2025
Q3
– Sell
-87,868
Closed -$1.19M – 990
2025
Q2
$1.19M Buy
87,868
+40,206
+84% +$583K 0.01% 788
2025
Q1
$757K Buy
+47,662
New +$548K ﹤0.01% 790
2024
Q1
– Sell
-175,000
Closed -$1.5M – 594
2023
Q4
$1.5M Hold
175,000
– – 0.02% 392
2023
Q3
$1.66M Hold
175,000
– – 0.02% 413
2023
Q2
$2.98M Hold
175,000
– – 0.04% 373
2023
Q1
$2.74M Buy
+175,000
New +$2.95M 0.04% 381

Other funds holding MLYS

Woodline Partners's MLYS Position: Q3 2026 in Review

Woodline Partners opened a new position in Mineralys Therapeutics (MLYS) in Q3 2026: 969,389 shares worth $24.4M. The stake represents 0.07% of the portfolio and ranks #355 among its holdings. This is a return to the name: Woodline Partners previously reported a position in MLYS as recently as Q2 2025.

Woodline Partners first reported a position in MLYS in Q1 2023 and has held it in 7 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Woodline Partners held 969,389 shares of Mineralys Therapeutics worth $24.4M as of Q3 2026.
  • Mineralys Therapeutics was a new Woodline Partners position in Q3 2026.
  • Mineralys Therapeutics made up 0.07% of Woodline Partners's portfolio in Q3 2026, its #355 holding.
  • Woodline Partners first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.